We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

10 hedge funds and large institutions have $365K invested in Northwest Biotherapeutics, Inc. Common stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 11 → 10 (-1)

24% less capital invested

Capital invested by funds: $482K → $365K (-$117K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$3.85K

Top Sellers

Rank Fund Capital Flow
1
AA
AlphaMark Advisors
Kentucky
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$251K +$3.85K +5,500 +2%
OCG
2
Opus Capital Group
Ohio
$42K – – –
WJWM
3
Williams Jones Wealth Management
New York
$30.8K – – –
MCM
4
MAI Capital Management
Ohio
$14K – – –
LDB
5
Lee, Danner & Bass
Tennessee
$14K – – –
AMG
6
Advisors Management Group
Wisconsin
$7K – – –
BCWM
7
Bartlett & Co Wealth Management
Ohio
$3.15K – – –
BC
8
Bartlett & Co
Ohio
$3K – – –
AA
9
AlphaMark Advisors
Kentucky
– -$13K -14,007 Closed

NWBO Hedge Fund Activity: Q4 2023 in Review

10 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2023, worth a combined $365K — down 24% from $482K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of NWBO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Moloney Securities Asset Management, adding an estimated $3.85K. The largest seller was AlphaMark Advisors, exiting entirely with an estimated $13K sold.

  • 10 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2023, down from 11 in Q3 2023.
  • Funds reported $365K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2023, down 24% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2023 and 1 closed out, a net change of -1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2023 was Moloney Securities Asset Management, an estimated $3.85K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2023 was AlphaMark Advisors, an estimated $13K sold.

Based on aggregated 13F filings for Q4 2023.